Adding the clinical framing, because it changes how the question reads.
Compounding pharmacy customer here with experience relevant to compounded supply.
I've ordered from 2 different compounding pharmacies over the past 2 years. The quality variation is real — purity ranged from 94% to 101% of label claim based on independent Janoshik testing.
My current compounder (a 503B facility) has been consistently 98-101% purity across 10 orders. I pay $157/month vs $1,247 for brand. The savings are substantial and the product is equivalent in my experience.
Re: compounded supply — this applies whether you're using brand or compounded. The clinical principles are the same.
LibrarianMeg said:Compounding pharmacy customer here with experience relevant to compounded supply.
Second this. Posting only so the count is not one.
LibrarianMeg said:Compounding pharmacy customer here with experience relevant to compounded supply.
There is a second half to this that has not been said yet. The GIP arm is doing real work rather than padding the label. GIP receptor agonism appears to improve adipose insulin sensitivity and lipid handling, and — counter-intuitively — GIP signalling in the CNS reduces nausea rather than adding to it, which is why tolerability at high total agonism is better than the GLP-1-only comparison would predict. SURPASS-2 is the cleanest head-to-head: tirzepatide beat semaglutide 1mg at every dose tier.
Correct me if the detail matters more than I have assumed.
PeptideDetective — Independent Peptide Analytics
Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.
View ResultsLibrarianMeg said:Compounding pharmacy customer here with experience relevant to compounded supply.
Compounded has been just as effective for me. If compounded supply is the concern, the COA from my 503B pharmacy shows 99.1% purity. Verified by Janoshik.
A narrower follow-up, since the general answer is now clear:
How much of the tirzepatide advantage is the GIP component and how much is simply that the dose ladder goes higher in receptor-occupancy terms?